CN1882535B - 2-氧代-1-吡咯烷衍生物的制备方法 - Google Patents
2-氧代-1-吡咯烷衍生物的制备方法 Download PDFInfo
- Publication number
- CN1882535B CN1882535B CN200480033998XA CN200480033998A CN1882535B CN 1882535 B CN1882535 B CN 1882535B CN 200480033998X A CN200480033998X A CN 200480033998XA CN 200480033998 A CN200480033998 A CN 200480033998A CN 1882535 B CN1882535 B CN 1882535B
- Authority
- CN
- China
- Prior art keywords
- general formula
- alkyl
- hydrogen
- oxo
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCCC(C1)CN([C@@](CC)C(*)=O)C1=O Chemical compound CCCC(C1)CN([C@@](CC)C(*)=O)C1=O 0.000 description 3
- KQMCGGGTJKNIMC-UHFFFAOYSA-N CCCC(C(O)O1)=CC1=O Chemical compound CCCC(C(O)O1)=CC1=O KQMCGGGTJKNIMC-UHFFFAOYSA-N 0.000 description 2
- HNNJFUDLLWOVKZ-VKHMYHEASA-N CC[C@@H](C(N)=O)N Chemical compound CC[C@@H](C(N)=O)N HNNJFUDLLWOVKZ-VKHMYHEASA-N 0.000 description 1
- KISFGRQEYHJUBG-YFKPBYRVSA-N CC[C@@H](C(N)=O)NCC Chemical compound CC[C@@H](C(N)=O)NCC KISFGRQEYHJUBG-YFKPBYRVSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (14)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03021534 | 2003-09-24 | ||
EP03021534.7 | 2003-09-24 | ||
PCT/EP2004/010212 WO2005028435A1 (en) | 2003-09-24 | 2004-09-13 | Process for preparing 2-oxo-1-pyrrolidine derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1882535A CN1882535A (zh) | 2006-12-20 |
CN1882535B true CN1882535B (zh) | 2011-05-11 |
Family
ID=34354424
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200480033998XA Active CN1882535B (zh) | 2003-09-24 | 2004-09-13 | 2-氧代-1-吡咯烷衍生物的制备方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US7629474B2 (zh) |
EP (1) | EP1667967B1 (zh) |
JP (1) | JP4658937B2 (zh) |
KR (1) | KR101124098B1 (zh) |
CN (1) | CN1882535B (zh) |
BR (1) | BRPI0414436A (zh) |
CA (1) | CA2538938C (zh) |
DK (1) | DK1667967T3 (zh) |
EA (1) | EA010306B1 (zh) |
ES (1) | ES2390455T3 (zh) |
HK (1) | HK1094702A1 (zh) |
IL (1) | IL174029A (zh) |
PL (1) | PL1667967T3 (zh) |
WO (1) | WO2005028435A1 (zh) |
ZA (1) | ZA200601970B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019242192A1 (zh) | 2018-06-20 | 2019-12-26 | 上海朴颐化学科技有限公司 | 一种布瓦西坦中间体、其制备方法及布瓦西坦的制备方法 |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1879861A2 (en) * | 2005-04-01 | 2008-01-23 | Rubamin Laboratories Limited | Process for preparing levetiracetam and racemization of (r)- and (s)-2-amino butynamide and the corresponding acid derivatives |
MY143249A (en) * | 2005-09-15 | 2011-04-15 | Ucb Pharma Sa | 4-substituted pyrrolidin-2-ones and their use |
JP2009518335A (ja) * | 2005-12-07 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | 3−カルボキシ−2−オキソ−1−ピロリジン誘導体及びそれらの使用 |
WO2016075082A1 (en) | 2014-11-10 | 2016-05-19 | Sandoz Ag | Stereoselective reductive amination of alpha-chiral aldehydes using omega-transaminases for the synthesis of precursors of pregabalin and brivaracetam |
KR102630456B1 (ko) | 2015-05-25 | 2024-01-29 | 쑤저우 펭슈 파마테크 씨오., 엘티디. | 브리바라세탐의 제조 방법 |
SI3371150T1 (sl) | 2015-11-03 | 2021-11-30 | UCB Biopharma SRL | Postopek za pripravo brivaracetama |
WO2017076737A1 (en) | 2015-11-03 | 2017-05-11 | Ucb Biopharma Sprl | Continuous process for preparing brivaracetam |
CN105646319B (zh) * | 2015-12-30 | 2018-05-18 | 佛山市隆信医药科技有限公司 | 一种布瓦西坦的制备方法 |
CN107513031B (zh) * | 2016-06-16 | 2022-08-02 | 上海医药集团股份有限公司 | 一种2-氧代-1-吡咯烷手性衍生物的制备方法 |
CN108218757A (zh) * | 2016-12-14 | 2018-06-29 | 上海医药集团股份有限公司 | 对2-(4-丙基吡咯烷-2-酮)-丁酰胺非对映异构体的拆分方法 |
CN106748950B (zh) * | 2017-01-13 | 2019-09-03 | 成都美域高制药有限公司 | 一种布瓦西坦及其中间体的制备方法 |
CN108658831B (zh) * | 2017-03-30 | 2021-11-05 | 江苏豪森药业集团有限公司 | 2-氧代-1-吡咯烷衍生物或其盐的制备方法 |
CN107793342A (zh) * | 2017-10-19 | 2018-03-13 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦的制备方法 |
CN108548873A (zh) * | 2018-03-20 | 2018-09-18 | 丽珠集团新北江制药股份有限公司 | 一种布瓦西坦中间体异构体的检测方法 |
CN108929289B (zh) * | 2018-06-19 | 2022-01-04 | 上海博氏医药科技有限公司 | 一种用于制备布瓦西坦的中间体化合物及其制备方法和用途 |
CN111333563B (zh) | 2018-12-19 | 2023-11-07 | 上海科胜药物研发有限公司 | 一种布瓦西坦中间体的制备方法 |
CN111892526A (zh) * | 2019-05-06 | 2020-11-06 | 北京万全德众医药生物技术有限公司 | 一种布瓦西坦的新制备方法 |
EP4144724A4 (en) | 2020-04-30 | 2023-03-15 | Shanghai Syncores Technologies Inc. Ltd. | BRIVARACETAM AND PROCESS FOR MAKING AN INTERMEDIATE THEREOF |
WO2023100110A1 (en) | 2021-12-02 | 2023-06-08 | Macfarlan Smith Limited | Process for preparing brivaracetam |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1404469A (zh) * | 2000-02-23 | 2003-03-19 | Ucb公司 | 2-氧代-1-吡咯烷衍生物、其制备方法和用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8412357D0 (en) * | 1984-05-15 | 1984-06-20 | Ucb Sa | Pharmaceutical composition |
GB8827389D0 (en) * | 1988-11-23 | 1988-12-29 | Ucb Sa | Process for preparation of(s)alpha-ethyl-2-oxo-1-pyrrolidineacetamide |
WO2002076451A1 (en) * | 2001-03-22 | 2002-10-03 | Ucb, S.A. | Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases |
EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
JP4334344B2 (ja) * | 2001-08-10 | 2009-09-30 | ユセベ ファルマ ソシエテ アノニム | オキソピロリジン化合物、当該化合物の調製、並びにレベチラセタム及び類似体の製造におけるその化合物の使用 |
-
2004
- 2004-09-13 CA CA2538938A patent/CA2538938C/en active Active
- 2004-09-13 EA EA200600485A patent/EA010306B1/ru not_active IP Right Cessation
- 2004-09-13 BR BRPI0414436-8A patent/BRPI0414436A/pt not_active Application Discontinuation
- 2004-09-13 ZA ZA200601970A patent/ZA200601970B/en unknown
- 2004-09-13 EP EP04765134A patent/EP1667967B1/en active Active
- 2004-09-13 JP JP2006527306A patent/JP4658937B2/ja active Active
- 2004-09-13 DK DK04765134.4T patent/DK1667967T3/da active
- 2004-09-13 PL PL04765134T patent/PL1667967T3/pl unknown
- 2004-09-13 CN CN200480033998XA patent/CN1882535B/zh active Active
- 2004-09-13 US US10/572,579 patent/US7629474B2/en active Active
- 2004-09-13 WO PCT/EP2004/010212 patent/WO2005028435A1/en active Application Filing
- 2004-09-13 KR KR1020067005793A patent/KR101124098B1/ko active IP Right Grant
- 2004-09-13 ES ES04765134T patent/ES2390455T3/es active Active
-
2006
- 2006-03-01 IL IL174029A patent/IL174029A/en active IP Right Grant
-
2007
- 2007-02-16 HK HK07101917.1A patent/HK1094702A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1404469A (zh) * | 2000-02-23 | 2003-03-19 | Ucb公司 | 2-氧代-1-吡咯烷衍生物、其制备方法和用途 |
Non-Patent Citations (5)
Title |
---|
Bourguignon J.J.,et al.Analogues of gamma-hydroxybutyricacid.Synthesisandbinding studies.J.Med.Chem31 5.1988,31(5),892-897. |
Bourguignon J.J.,et al.Analogues of gamma-hydroxybutyricacid.Synthesisandbinding studies.J.Med.Chem31 5.1988,31(5),892-897. * |
Bourguignon J.J.,et al.Lactone Chemistry. Synthesis of beta-substituted,gamma-functionalized butanolides and butenolides andsuccinaldehydic acids from glyoxylic acid.J.Org.Chem46 24.1981,46(24),4889-4894,尤其是第4890页第2栏表II、倒数第二段. * |
BourguignonJ.J. et al.Lactone Chemistry. Synthesis of beta-substituted |
David D.P.Laffan,et al.An efficient synthesis of racemic4-hydroxy-2-oxo-1-pyrrolidineacetamide(Oxiacetam) usingtetramic-acid intermediates.HELV.CHIM.ACTA75.1992,75892-900. * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019242192A1 (zh) | 2018-06-20 | 2019-12-26 | 上海朴颐化学科技有限公司 | 一种布瓦西坦中间体、其制备方法及布瓦西坦的制备方法 |
US11518741B2 (en) | 2018-06-20 | 2022-12-06 | Shanghai Puyi Chemical Co., Ltd. | Brivaracetam intermediate, preparation method therefor, and preparation method for brivaracetam |
Also Published As
Publication number | Publication date |
---|---|
EP1667967B1 (en) | 2012-08-01 |
JP4658937B2 (ja) | 2011-03-23 |
EA200600485A1 (ru) | 2007-02-27 |
IL174029A (en) | 2012-06-28 |
PL1667967T3 (pl) | 2012-11-30 |
AU2004274157A1 (en) | 2005-03-31 |
JP2007515387A (ja) | 2007-06-14 |
BRPI0414436A (pt) | 2006-11-14 |
DK1667967T3 (da) | 2012-10-08 |
US20070100150A1 (en) | 2007-05-03 |
IL174029A0 (en) | 2006-08-01 |
US7629474B2 (en) | 2009-12-08 |
CN1882535A (zh) | 2006-12-20 |
CA2538938A1 (en) | 2005-03-31 |
EA010306B1 (ru) | 2008-08-29 |
HK1094702A1 (zh) | 2007-04-04 |
KR101124098B1 (ko) | 2012-03-21 |
CA2538938C (en) | 2011-08-09 |
WO2005028435A1 (en) | 2005-03-31 |
ES2390455T3 (es) | 2012-11-13 |
KR20060121889A (ko) | 2006-11-29 |
EP1667967A1 (en) | 2006-06-14 |
ZA200601970B (en) | 2007-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1882535B (zh) | 2-氧代-1-吡咯烷衍生物的制备方法 | |
CA2401048C (en) | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses | |
KR101159870B1 (ko) | 분자내 알릴화에 의해 2-옥소-1-피롤리딘 유도체를제조하는 방법 | |
CN101415670A (zh) | 制备磺酰胺取代醇和其中间体的方法 | |
CN111527077A (zh) | 通过添加o,o′-二取代酒石酸对映异构体进行外消旋烟碱的对映异构体分离 | |
KR100704590B1 (ko) | (+)-시스-세르트랄린의 신규한 제조 방법 | |
WO2007065634A1 (en) | 3-carboxy- 2-oxo-1 -pyrrolidine derivatives and their uses | |
CN101511786A (zh) | 制备左乙拉西坦的方法 | |
RU2181358C2 (ru) | Способ получения сертралина из хирального тетралона | |
HRP20000473A2 (en) | Novel process for preparing a ketamine | |
DE60104923T2 (de) | Piperidin- und Pirazinverbindungen zur Verwendung in der Behandlung von Alzheimer | |
AU2004274157B2 (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
CA2474323A1 (en) | Method of obtaining citalopram | |
KR100464183B1 (ko) | 이소인돌린의 제조방법 | |
MXPA06003024A (en) | Process for preparing 2-oxo-1-pyrrolidine derivatives | |
JP5635073B2 (ja) | アミノシクロブタンまたはアミノシクロブテンの誘導体、これらの製造方法、および医薬品としてのこれらの使用 | |
WO1999065318A2 (de) | Germinal substituierte amine | |
DD301657A9 (de) | Verfahren zur herstellung von zwischenprodukten fuer bis (benzylpyrrolidin)-dopanin-agonisten | |
JPH0570429A (ja) | 3−アザビシクロ〔3, 3, 0〕オクタンの製造方法 | |
DE10233724A1 (de) | Verfahren zur Herstellung von 3-Hydroxy-(2-thienyl)propanaminen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1094702 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: UCB MEDICINE STOCK CO., LTD. Free format text: FORMER OWNER: UCB SA Effective date: 20071207 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20071207 Address after: Brussels Applicant after: UCB SA Address before: Brussels Applicant before: UCB SA |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1094702 Country of ref document: HK |